GB/T 16886.1-2022
ActiveBiological evaluation of medical devices—Part 1: Evaluation and testing within a risk management process
医疗器械生物学评价 第1部分：风险管理过程中的评价与试验
Application Summary AI generated
This standard specifies the framework for evaluating the biological safety of medical devices within a risk management process. It is applied by manufacturers and testing laboratories to determine the need for biological testing based on device contact duration and tissue type, ensuring compliance with regulatory requirements for market approval. The standard is critical for guiding the selection of appropriate biocompatibility tests for materials used in medical devices, such as implants, surgical instruments, and diagnostic equipment.
Related Standards
GB/T 19634-2005
In vitro diagnostic test systems-General technical requirements for blood-glucose monitoring systems for self-testing
GB/T 47486-2026
General technical requirements for vasculature-on-a-chip
GB/Z 30154-2013
Medical laboratories―Guidance on laboratory implementation of GB/T 22576-2008
GB/Z 16886.22-2022
Biological evaluation of medical devices—Part 22:Guidance on nanomaterials
GB/Z 43280-2023
Medical laboratories—Practical guidance for the estimation of measurement uncertainty
GB/Z 43281-2023
Guidance for supervisors and operators of point-of-care testing(POCT) devices
GB/Z 44363-2024
Pyrogenicity—Principles and methods for pyrogen testing of medical devices
GB/Z 157-2026
In vitro diagnostic test systems—Requirements and recommendations for detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by nucleic acid amplification methods
Transparency note: The application summary and key sentences on this page were automatically generated by AI from the standard's original text. This content has not been human-verified and should not be used for compliance or regulatory purposes. Always refer to the official standard document from the issuing authority.